Literature DB >> 22305633

IgM-phosphorylcholine autoantibodies and outcome in acute coronary syndromes.

Kenneth Caidahl1, Marianne Hartford, Thomas Karlsson, Johan Herlitz, Knut Pettersson, Ulf de Faire, Johan Frostegård.   

Abstract

BACKGROUND: Antibodies against proinflammatory phosphorylcholine (anti-PC) seem to be protective and reduce morbidity. We sought to determine whether low levels of immunoglobulin-M (IgM) autoantibodies against PC add prognostic information in acute coronary syndromes (ACS).
METHODS: IgM anti-PC titers were measured in serum obtained within 24h of admission from 1185 ACS patients (median age 66 years, 30% women). We evaluated major acute cardiovascular events (MACE) and all-cause mortality short--(6 months), intermediate--(18 months) and long--(72 months) terms.
RESULTS: Low anti-PC titers were associated with MACE and all-cause mortality at all follow-up times. After adjusting for clinical variables, plasma troponin-I, proBNP and CRP levels, associations remained at all times with MACE, short and intermediate terms also with all-cause mortality. With anti-PC titers below median, adjusted hazard ratios at 18months were for MACE 1.79 (95% confidence interval [CI]: 1.31 to 2.44; p=0.0002) and for all-cause mortality 2.28 (95% CI: 1.32 to 3.92; p=0.003). Anti-PC and plasma CRP were unrelated and added to risk prediction.
CONCLUSIONS: Serum IgM anti-PC titers provide prognostic information above traditional risk factors in ACS. The ease of measurement and potential therapeutic perspective indicate that it may be a valuable novel biomarker in ACS.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22305633     DOI: 10.1016/j.ijcard.2012.01.018

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  18 in total

1.  Low levels of natural IgM antibodies against phosphorylcholine are independently associated with vascular remodeling in patients with coronary artery disease.

Authors:  Christian A Gleissner; Christian Erbel; Julia Haeussler; Mohammadreza Akhavanpoor; Gabriele Domschke; Fabian Linden; Andreas O Doesch; Göran Conradson; Sebastian J Buss; Nina P Hofmann; Gitsios Gitsioudis; Hugo A Katus; Grigorios Korosoglou
Journal:  Clin Res Cardiol       Date:  2014-08-08       Impact factor: 5.460

Review 2.  Microbial modulation of host immunity with the small molecule phosphorylcholine.

Authors:  Sarah E Clark; Jeffrey N Weiser
Journal:  Infect Immun       Date:  2012-12-10       Impact factor: 3.441

3.  Low levels of a natural IgM antibody are associated with vein graft stenosis and failure.

Authors:  Michael Sobel; Katherine I Moreno; Mayumi Yagi; Ted R Kohler; Gale L Tang; Alexander W Clowes; Xiao-Hua A Zhou; Evercita Eugenio
Journal:  J Vasc Surg       Date:  2013-07-13       Impact factor: 4.268

Review 4.  Trained Immunity as a Trigger for Atherosclerotic Cardiovascular Disease-A Literature Review.

Authors:  Natalia Anna Zieleniewska; Małgorzata Kazberuk; Małgorzata Chlabicz; Andrzej Eljaszewicz; Karol Kamiński
Journal:  J Clin Med       Date:  2022-06-12       Impact factor: 4.964

5.  A genome-wide association study of IgM antibody against phosphorylcholine: shared genetics and phenotypic relationship to chronic lymphocytic leukemia.

Authors:  Xu Chen; Stefan Gustafsson; Thomas Whitington; Yan Borné; Erik Lorentzen; Jitong Sun; Peter Almgren; Jun Su; Robert Karlsson; Jie Song; Yi Lu; Yiqiang Zhan; Sara Hägg; Per Svensson; Karin E Smedby; Susan L Slager; Erik Ingelsson; Cecilia M Lindgren; Andrew P Morris; Olle Melander; Thomas Karlsson; Ulf de Faire; Kenneth Caidahl; Gunnar Engström; Lars Lind; Mikael C I Karlsson; Nancy L Pedersen; Johan Frostegård; Patrik K E Magnusson
Journal:  Hum Mol Genet       Date:  2018-05-15       Impact factor: 6.150

6.  Autoantibodies to phosphorylcholine and cardiovascular outcomes in patients with acute coronary syndromes in the ATLAS ACS-TIMI 46 trial.

Authors:  Bram J Geller; Jessica L Mega; David A Morrow; Jianping Guo; Elaine B Hoffman; C Michael Gibson; Christian T Ruff
Journal:  J Thromb Thrombolysis       Date:  2014-04       Impact factor: 2.300

7.  Immunoglobulin (Ig)M antibodies against oxidized cardiolipin but not native cardiolipin are novel biomarkers in haemodialysis patients, associated negatively with mortality.

Authors:  A G Frostegård; X Hua; J Su; J J Carrero; O Heimbürger; P Bárány; P Stenvinkel; J Frostegård
Journal:  Clin Exp Immunol       Date:  2013-12       Impact factor: 4.330

Review 8.  Natural IgM: beneficial autoantibodies for the control of inflammatory and autoimmune disease.

Authors:  Caroline Grönwall; Gregg J Silverman
Journal:  J Clin Immunol       Date:  2014-04-02       Impact factor: 8.317

9.  Low levels of IgM antibodies to oxidized cardiolipin increase and high levels decrease risk of cardiovascular disease among 60-year olds: a prospective study.

Authors:  Jun Su; Xiang Hua; Max Vikström; Karin Leander; Bruna Gigante; Mai-Lis Hellenius; Ulf de Faire; Johan Frostegård
Journal:  BMC Cardiovasc Disord       Date:  2013-01-07       Impact factor: 2.298

10.  Passive immunization with hypochlorite-oxLDL specific antibodies reduces plaque volume in LDL receptor-deficient mice.

Authors:  Marcella van Leeuwen; Michael J Kemna; Menno P J de Winther; Louis Boon; Adriaan M Duijvestijn; Darius Henatsch; Nico A Bos; Marion J J Gijbels; Jan Willem Cohen Tervaert
Journal:  PLoS One       Date:  2013-07-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.